翼状胬肉治疗中应用贝伐单抗的疗效的Meta分析

Meta-analysis on efficacy of bevacizumab in pterygium treatment

目的探讨贝伐单抗（bevacizumab）在翼状胬肉治疗中的临床疗效。设计Meta分析。研究对象国内外于从2001年1月1日至2014年9月30日发表的以翼状胬肉患者作为研究对象,治疗方案采用贝伐单抗与对照组相比的随机对照试验。方法应用循证医学的研究方法检索美国国立医学图书馆、荷兰医学文摘、循证医学数据库、中国知网、万方数据库、中国期刊全文数据库及维普中文科技期刊数据库并辅以手工检索,遵循Cochrane Handbook 5.0偏倚风险评估工具评价纳入研究的质量,采用Rev Man 5.0和SPSS 10.0软件进行统计学处理。主要指标贝伐单抗用于翼状胬肉的复发率和并发症的比值比（OR）。结果纳入7项随机对照试验,共398眼。分析结果显示：与空白对照组相比,贝伐单抗组在防止胬肉复发方面,差异无统计学意义[OR=0.60,95%CI（0.34~1.05）,P=0.07,I2=7%];在术后并发症方面,两组比较差异无统计学意义[OR=0.68,95%CI（0.38~1.22）,P=0.19,I2=0%]。结论在翼状胬肉治疗中,应用贝伐单抗不能降低复发率。

Objective To evaluate the clinical efficacy of bevacizumab for pterygium treatment. Design Meta-analysis. Participants The randomized controled trials on the efficacy and complications in treatment of pterygium by bevacizumab. Methods Search was conducted in Pubmed, EMbase, Cochrane Library, CNKI, Wanfang database, CBM and VIP, and hand-search was also performed.The qualities of the randomized controlled trials（RCT） were evaluated according to the Cochrane Handbook for Systematic Reviews of Interventions Version 5.0. The softwares Rev Man 5.0 and SPSS10.0 were used for Meta-analysis. Main Outcome Measures The Odds ratio（OR） of the recurrence rate and the complications in treatment of pterygium by bevacizumab. Results Only 7 trials were included,involving 398 eyes. Meta-analysis showed that significant difference was not found between the bevacizumab and the control in recur-rence [OR=0.60, 95%CI（0.34-1.05）, P=0.07, I2=7%]. There was also no difference in reducing the complications[OR=0.68, 95%CI（0.38-1.22）, P =0.19, I2=0% ]. Conclusion Bevacizumab in pterygium treatment does not reduce pterygium recurrence.